{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T08:19:39Z","timestamp":1772180379412,"version":"3.50.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>We report on a 38-year-old patient who presented with rapidly progressive interstitial lung disease (ILD), without any signs of muscular involvement. Antinuclear antibody testing by indirect immunofluorescence revealed a nuclear titer of 1:320 with a fine speckled and a cytoplasmic titer of 1:1\u2019280 with a fine speckled pattern. Subsequent myositis-specific and myositis-associated antibody tests with commercial multiplex dot-immunoassays showed a strong positive result for anti-Ha antibodies, also confirmed by protein immunoprecipitation, establishing the diagnosis of anti-synthetase syndrome with associated ILD. Despite initial improvement after treatment with intravenous cyclophosphamide and high dose steroids, he relapsed shortly after, with additional muscular symptoms. Subsequent escalation of therapy with rituximab resulted in sustained remission. Considering the scarcity of data about the clinical presentation and prognosis of patients with anti-Ha antibodies, our report provides additional information on diagnostic challenges and therapeutic response in these patients.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1750916","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T06:51:37Z","timestamp":1772175097000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-Ha anti-synthetase syndrome presenting as rapidly progressive interstitial lung disease: a case report of high confidence autoantibody testing"],"prefix":"10.3389","volume":"17","author":[{"given":"Alina G.","family":"Liedtke","sequence":"first","affiliation":[{"name":"Clinic of Respiratory Medicine, University Hospital Basel","place":["Basel, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Daikeler","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital of Basel","place":["Basel, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Gherca","sequence":"additional","affiliation":[{"name":"Clinic of Radiology and Nuclear Medicine, University Hospital of Basel","place":["Basel, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias J.","family":"Herrmann","sequence":"additional","affiliation":[{"name":"Clinic of Respiratory Medicine, University Hospital Basel","place":["Basel, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spasenija","family":"Savic Prince","sequence":"additional","affiliation":[{"name":"Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel","place":["Basel, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah L.","family":"Tansley","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, University of Bath","place":["Bath, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingmar A. F. M.","family":"Heijnen","sequence":"additional","affiliation":[{"name":"Division Medical Immunology, Laboratory Medicine, University Hospital Basel","place":["Basel, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin E.","family":"Hostettler","sequence":"additional","affiliation":[{"name":"Clinic of Respiratory Medicine, University Hospital Basel","place":["Basel, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-20-3328","article-title":"A narrative review of interstitial lung disease in anti-synthetase syndrome: a clinical approach","volume":"13","author":"Sawal","year":"2021","journal-title":"J Thorac Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.866087","article-title":"Aminoacyl-tRNA synthetases: on anti-synthetase syndrome and beyond","volume":"13","author":"Galindo-Feria","year":"2022","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41584-024-01188-4","article-title":"An update on autoantibodies in the idiopathic inflammatory myopathies","volume":"21","author":"Allameen","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa021","article-title":"The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity","volume":"59","author":"Tansley","year":"2020","journal-title":"Rheumatol (Oxford)."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/s14zq8","article-title":"Agreement between local and central anti-synthetase antibodies detection: results from the Classification Criteria of Anti-Synthetase Syndrome project biobank","volume":"42","author":"Loganathan","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000001039","article-title":"Autoantibody testing in myositis: an update","volume":"36","author":"McMorrow","year":"2024","journal-title":"Curr Opin Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"104453","DOI":"10.1016\/j.nmd.2024.104453","article-title":"273rd ENMC International workshop: Clinico-Sero-morphological classification of the Antisynthetase syndrome. Amsterdam, The Netherlands, 27\u201329 October 2023","volume":"45","author":"Stenzel","year":"2024","journal-title":"Neuromuscul Disord"},{"key":"B9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J Autoimmun"},{"key":"B10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.semarthrit.2020.09.020","article-title":"Antisynthetase syndrome - much more than just a myopathy","volume":"51","author":"Opinc","year":"2021","journal-title":"Semin Arthritis Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/art.40320","article-title":"2017 European league against rheumatism\/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B12","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.3390\/jcm8112013","article-title":"Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course","volume":"8","author":"Cavagna","year":"2019","journal-title":"J Clin Med"},{"key":"B13","first-page":"S312","article-title":"Identification of autoantibodies to tyrosyl-tRNA synthetase in dermatomyositis with features consistent with antisynthetase syndrome (abstract)","volume":"52","author":"Hashish","year":"2005","journal-title":"Arthritis Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-017-8974-3","article-title":"Reflex testing of speckled cytoplasmic patterns observed in routine ANA HEp-2 indirect immunofluorescence with a multiplex anti-synthetase dot-blot assay: a multicentric pilot study","volume":"66","author":"Infantino","year":"2018","journal-title":"Immunologic Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.3390\/jcm9092944","article-title":"Prevalence of novel myositis autoantibodies in a large cohort of patients with interstitial lung disease","volume":"9","author":"Moll","year":"2020","journal-title":"J Clin Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"103403","DOI":"10.1016\/j.autrev.2023.103403","article-title":"Autoantibodies against tyrosyl-tRNA synthetase (anti-Ha antibodies)","volume":"22","author":"Yamano","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1614777","article-title":"Acute exacerbation of anti-Ha antibody-positive antisynthetase syndrome-associated interstitial lung disease: a case report","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"102951","DOI":"10.1016\/j.jaut.2022.102951","article-title":"Autoantigenic properties of the aminoacyl tRNA synthetase family in idiopathic inflammatory myopathies","volume":"134","author":"Preger","year":"2023","journal-title":"J Autoimmunity."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e61251","DOI":"10.7759\/cureus.61251","article-title":"Anti-ha antisynthetase syndrome: A case report","volume":"16","author":"De Andrade","year":"2024","journal-title":"Cureus."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1136\/annrheumdis-2017-212915","article-title":"Detection of myositis-specific antibodies","volume":"78","author":"Vulsteke","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-023-05279-5","article-title":"Myositis autoantibodies detected by line blot immunoassay: clinical associations and correlation with antibody signal intensity","volume":"43","author":"Loarce-Martos","year":"2023","journal-title":"Rheumatol Int"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14174","article-title":"Performance of myositis-specific antibodies detected on myositis line immunoassay to diagnose and sub-classify patients with suspected idiopathic inflammatory myopathy, a retrospective records-based review","volume":"24","author":"Beaton","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae245","article-title":"Combination of cytoplasmic and nuclear patterns on Hep-2 antinuclear antibody is useful as a screening test for anti-synthetase syndrome","volume":"63","author":"Yoshida","year":"2024","journal-title":"Rheumatol (Oxford)."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/art.43038","article-title":"Clinical characteristics of anti-synthetase syndrome: analysis from the classification criteria for anti-synthetase syndrome project","volume":"77","author":"Faghihi-Kashani","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.07.013","article-title":"Treatment of idiopathic inflammatory myositis associated interstitial lung disease: A systematic review and meta-analysis","volume":"18","author":"Barba","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170541","article-title":"Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: A multicenter retrospective case review","volume":"45","author":"Doyle","year":"2018","journal-title":"J Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker088","article-title":"Rituximab treatment in patients with refractory inflammatory myopathies","volume":"50","author":"Mahler","year":"2011","journal-title":"Rheumatol (Oxford)."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1750916\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T06:51:38Z","timestamp":1772175098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1750916\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2026.1750916"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1750916","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"article-number":"1750916"}}